SynthesisBMC cancer2026
Increased incidence of diabetes mellitus in hematological malignancies: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to systematically review the incidence of diabetes mellitus (DM) in patients with preexisting hematological malignancy (HM) and investigate the risk factors contributing to DM incidence.
methodsA systematic search was performed in PubMed, Scopus, Web of Science, and Google Scholar according to PRISMA guidelines. Pooled estimates were calculated using a random-effects model with restricted maximum likelihood (REML) estimation of between-study variance and the Hartung–Knapp adjustment for confidence intervals (CIs). Heterogeneity was assessed using the Q test, τ², I², and 95% prediction intervals, with I² values above 50% indicating substantial variability. Additionally, we performed subgroup analyses based on relevant risk factors. Publication bias and small-study effects were evaluated using funnel plots and Egger’s test, and influence diagnostics were performed through leave-one-out analyses.
resultsA total of 37 studies were included in this study. An increased pooled risk measure of 2.83 (95% CI: 2.12–3.77) for DM incidence was reported in the HM group compared to the control group. Among reported risk factors, obesity (2.10, 95% CI: 1.10–3.99), receiving total body irradiation (TBI) (2.08, 95% CI: 1.58–6.02), dyslipidemia (2.60, 95% CI: 1.09–6.20), and HLA mismatch (1.56, 95% CI: 1.13–2.15) demonstrated significant association with a higher incidence of DM among HM patients. However, no significant association was observed between DM incidence and risk factors including sex, hypertension (HTN), type of donor in bone marrow transplant, graft-versus-host disease (GvHD), positive DM family history, and anthracycline usage.
conclusionThe meta-analysis supports the hypothesis that DM incidence is significantly higher in HM patients, which requires early prevention and effective intervention for this population. Yet, more prospective studies with high sample sizes and follow-up duration are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.